Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.
Blood tests and microbiome profiles may soon replace traditional imaging, enabling smarter decisions about cancer treatment intensity.
Convergence of ctDNA-based molecular residual disease detection, fecal microbiome profiling, and systemic inflammatory immune scores into multimodal 'Digital Twin' frameworks promises to replace conventional anatomical staging for CRC and guide personalized adjuvant chemotherapy de-escalation or escalation. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Comprehensive review
- Category
- early_cancer_detection
- Maturity
- Validated
Why it surfaced
Synthesizes the rapidly evolving CRC non-invasive biomarker space (ctDNA, microbiome, immune scores); timely for clinical practice and pipeline development in ctDNA-guided therapy decisions. Cross-lists with precision oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.